Bupivacaine Hydrochloride and Epinephrine Bitartrate Injection Shortage Update
Areazine synthesizes this FDA drug-shortage notice directly from FDA's official public data feed. See our methodology for full source attribution and refresh cadence.
The FDA reports a current shortage of Bupivacaine Hydrochloride and Epinephrine Bitartrate Injection, with specific presentations currently unavailable from Fresenius Kabi USA.
What this FDA drug-shortage notice tells you, and what most readers miss
This notice was issued by FDA on April 6, 2026 and geographically references United States. Its severity classification of "low" signals how the issuing agency weighs the risk of harm if no action is taken - "critical" and "high" tier alerts typically carry direct consumer actions, while "medium" and "low" tend toward informational guidance or monitoring advisories. The category it belongs to - Drug Shortages - determines the regulatory framework behind it, which shapes what mitigations (alternative therapies, allocation timelines, manufacturer guidance) are available and which agency holds oversight.
Most readers skim a notice like this, check whether they are personally affected, and move on. The more useful lens is to verify its scope, source, and timestamp, then compare related notices without assuming that one record proves a broader trend.
Areazine pairs this record with the original agency URL so you can check the primary source before acting. Its related labels are drug-shortage, fda, medication, Bupivacaine.
What's in Shortage
Bupivacaine Hydrochloride and Epinephrine Bitartrate Injection (Brand names: SENSORCAINE, SENSORCAINE MPF) is currently listed in shortage. This medication is an injection used within the therapeutic category of Anesthesia. While several presentations remain available, the FDA classifies the overall status of this drug as a "Current" shortage.
Which Manufacturers Are Affected
Fresenius Kabi USA, LLC
- Status: Limited Availability
- Contact: 888-386-1300
- Availability Details:
- Unavailable: Sensorcaine, Injection, 5 mg/1 mL; .005 mg/1 mL (NDC 63323-462-31).
- Available: The following presentations are currently available, though the manufacturer recommends checking wholesalers for inventory:
- Sensorcaine, Injection, 5 mg/1 mL; .005 mg/1 mL (NDC 63323-463-57)
- Sensorcaine, Injection, 2.5 mg/1 mL; .005 mg/1 mL (NDC 63323-468-37)
- Sensorcaine, Injection, 2.5 mg/1 mL; .005 mg/1 mL (NDC 63323-468-17)
- Sensorcaine, Injection, 7.5 mg/1 mL; .005 mg/1 mL (NDC 63323-460-37)
- Sensorcaine, Injection, 5 mg/1 mL; .005 mg/1 mL (NDC 63323-462-17)
- Sensorcaine, Injection, 2.5 mg/1 mL; .005 mg/1 mL (NDC 63323-461-57)
- Sensorcaine, Injection, 5 mg/1 mL; .005 mg/1 mL (NDC 63323-462-37)
Why There's a Shortage
No specific reason for this shortage was provided in the source data.
What Patients Should Do
If you are scheduled for a procedure requiring anesthesia, please be aware of this supply update. Patients should:
- Consult with their healthcare provider or surgeon regarding the availability of specific medications for their procedure.
- Speak with a pharmacist for the most current local inventory information.
- Contact the manufacturer, Fresenius Kabi USA, at 888-386-1300 for specific product inquiries.
Disclaimer: Patients should always consult their healthcare provider for medical advice and to discuss alternative treatment options.
Source
Attribution: FDA Drug Shortage Database Initial Posting Date: 02/20/2018 Last Updated: 02/05/2026
Original source: FDA Official Notice ↗
Related Drug Shortages
All Drug Shortages →Frequently Asked Questions
Common questions about this FDA drug-shortage notice.